Possible scenario
Regulatory Backlash
20% Chance
Lawmakers, patient advocates, and academic medical centers challenge the program over transparency, bias, informed consent, and whether AI evidence could weaken safety standards. HHS keeps the initiative alive but faces hearings, guidance delays, and stricter data-governance requirements.
Secondary impacts
- Healthcare -1.1%
- Technology -0.7%
- Business Services +0.2%
Tickers
- RXRX-4.5%
- TEM-4.3%
- SDGR-3.8%
- +0.8%
Portfolio impact
S&P 500-0.4%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.